Remdesivir for Patients Hospitalized With COVID-19: Evidence of Effectiveness From Cohort Studies in the Omicron Era

Clin Infect Dis. 2024 Dec 13;79(Supplement_4):S127-S130. doi: 10.1093/cid/ciae515.

Abstract

Remdesivir is the only antiviral approved for treatment of persons hospitalized for coronavirus disease 2019 (COVID-19). This supplement presents new information from real-world cohort studies that report reduced mortality in at-risk populations and reduction in readmission for COVID-19 in the Omicron era.

Keywords: COVID-19; antivirals; cohort studies; real-world evidence; remdesivir.